血管紧张素转换酶抑制剂、血管紧张素Ⅱ受体拮抗剂治疗冠心病

Angiotensin Converting Enzyme Inhibitors and Angiotensin Ⅱ Receptor Blockers in Treating Coronary Heart Disease

比较血管紧张素转换酶抑制剂(ACEI)与血管紧张素Ⅱ受体拮抗剂(ARB)治疗冠心病的疗效:在全因死亡、心血管死亡、心肌梗死及心力衰竭治疗方面,ARB与ACEI无明显差异,但ARB因不良反应而停药方面优于ACEI。结论:ARB治疗冠心病在全因死亡、心血管死亡、心肌梗死及心力衰竭治疗方面,疗效与ACEI相似而耐受性更好。

In comparison to the effect of angiotensin converting enzyme inhibitors （ ACEI ） and angiotensin Ⅱ receptor blockers （ ARB ） in treating coronary heart disease：in all-cause mortality and cardiovascular mortality ,myocardial infarction and heart failure, there was no statistically significant difference of the ARB and in ACEI, but ARB excels in ACEI discontinuation due to adverse reactions. Conclusion ： the current evidence suggests that ARB is as effective as ACEI in reducing the risk of patients with all-cause mortalily, cardiovascular mortality, myocardial infarction and heart failure and better tolerated.